HalioDx said that Chinese oncologists will gain access to its Immunoscore assay for predicting the risk of recurrence of early-stage colon cancer.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The firm said that the new instrument, which prepares slides for cytology and aliquot samples for molecular testing, offers workflow benefits to clinical labs.
The diagnostic can now be used to identify a wider range of patients with stage III or metastatic NSCLC who may benefit from first-line treatment with Keytruda.
Decreased sales in the firm's centralized and point-of-care business and diabetes care business were partially offset by strong growth in the molecular diagnostics business.
The iPod-sized system integrates a microcontroller, a peristaltic pump, heparin injector, and microfluidic chip to capture tumor cells in a patient's bloodstream.
The investment bank gave the liquid biopsy company a price target of $90 and said that it views Guardant as the field leader.
The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
Orto+ will be market and distribute Todos' TM-B2 test for breast cancer screening in Romania and Austria. The test is CE marked.
Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Sophia's STS molecular diagnostic application runs on top of the Sophia AI platform to detect and characterize genomic alterations in solid tumors.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
The firm said that it will use the funding to support business activities to meet demand for its approach to clinical trial recruitment.
Beckman Coulter got regulatory clearance for three in vitro diagnostic products, including its DxH 520 hematology analyzer for low-volume clinical labs.